Director, Deal Advisory
+41 58 249 58 16
Swap, don’t sell: Driving value through asset swaps
The Swiss Pharmaceuticals sector produced four USD1 billion+ deals in the first half of 2018. This is not surprising given the efforts by Pharmaceuticals and Life Sciences businesses to push new boundaries and continuously innovate.
The beneficial ownership register leads to further transparency
Robots – don’t fear them, use them
Swiss Life Sciences – ready for R&D 2030?
Why EU data protection regulation also concerns Switzerland